In Vitro | Nano Publications

2018 – AACR – Activation of the cGAS-STING pathway by NBTXR3

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Recent studies reported that radiotherapy could activate the cGAS-STING pathway, which plays a fundamental role in the immune response to cytoplasmic DNA, by activation of the transcriptional factor IRF3, leading to expression of interferon-beta. Moreover, cGAS-STING activation appears to be an important component for tumor resident Antigen-Presenting Cells activation, a crucial step for induction of CD8+ T cell response against tumor derived antigens. […]

2017 – Abstract – 35th CFS – Hafnium Oxide Nanoparticles: An Emergent Promising Treatment for Solid Tumors

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Hafnium oxide nanoparticles: an emergent promising treatment for solid tumors To improve tumor response, radiotherapy (RT) has been combined with chemical agents, radiosensitizers and monoclonal antibodies. However, the complexity of these associations in terms of pharmacology, local control, clinical outcome benefits or patient quality of life underlines the need for the development of new therapeutic approaches. […]

2017 – Abstract Conference Immunotherapy Radiotherapy Combinations NYC

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3, In Vivo

Hafnium oxide, an electron-dense material, was designed at the nanoscale to increase the radiation dose deposited from within the cancer cells: “Hot spot” of energy deposit where the nanoparticles are when exposed to radiation therapy (RT). Preclinical studies have demonstrated increase of cancer cells killing in vitro and marked antitumor efficacy in vivo with presence of these nanoparticles […]

2017 – AACR Abstract – NBTXR3 combination with cisplatin in vivo and in vitro

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3, In Vivo

Combination of NBTXR3 and cisplatin has been evaluated in vitro and in vivo. No specific toxicity was observed for the cells exposed only to NBTXR3. For the combined treatment, a marked and enhanced cell destruction when compared to the single agent. In vivo, NBTXR3 combined with low dose of cisplatin delayed tumor growth when compared to single agent CDDP in combination with RT. NBTXR3 is intended to be injected in the tumors. Spilling in the circulation may occur during product administration or, as expected, during tumor destruction, leading to steady trapping of NPs in the reticulo-endothelial system (liver and spleen). Clinically, it is unknown whether patients, previously treated with NPs, may show toxic signs when NPs are exposed (activation) to diagnosis imaging (computed tomography(CT)) of the liver.

2011 – ECCO Abstract – NBTXR3 as promising cancer therapy – Magiorella et al.

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

We created and developed NBTXR3 nanoparticles with a crystalline hafnium oxide core which provide high electron density structure and inert behavior in biological media. NBTXR3 nanoparticles’ characteristics, size, charge and shape, allow for efficient interaction with biological entities, cell membrane binding and cellular uptake. The nanoparticles were shown to form clusters at the subcellular level in tumor models. Of most importance, we show NBTXR3 intratumor bioavailability with dispersion of nanoparticles in the three dimensions and persistence within the tumor structure, supporting the use of NBTXR3 as effective antitumor therapeutic agent.

2011 – AACR Abstract – NBTXR3 radioenhancement and anti-tumor effect in vitro – Magiorella et al.

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Local and systemic control of Soft Tissue Sarcoma (STS) remains a clinical challenge. Radiation therapy is part of the standard of care of STS. The narrowness of its therapeutic window represents the main concern for different clinical settings. Thus, local delivery of radiation doses is critical to ensure optimal benefit-risk ratio. NBTXR3, biocompatible hafnium oxide nanoparticles were designed as therapeutics to be activated by ionizing radiation to achieve tumor control by enhancement of local energy deposition.

2010 – ESTRO Abstract – hafnium Oxide nanoparticles as anti cancer agent – Deutsch et al.

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Nanotechnology is the engineering of objects at the nanometer scale with novel properties. Nanotechnology is being applied to medicine leading to novel diagnostic or treatment applications. Nanoscale objects are about one hundred to ten thousand times smaller than human cells. They are similar in size to large biological molecules ("biomolecules") such as enzymes and receptors. As an example, hemoglobin, the molecule that carries oxygen in red blood cells, is approximately 5 nanometers in diameter. Nanoscale objects smaller than 100 nanometers can move out of blood vessels as they circulate through the body due to morphological features of the endothelium (fenestrae size). Those smaller than 7 nanometers can be cleared from the body by the kidney, as they circulate.